PREMEDICATION AND THE INCIDENCE AND SEVERITY OF INFUSION-RELATED REACTIONS IN PATIENTS TREATED WITH CETUXIMAB: DATA FROM THE CRYSTAL AND MABEL STUDIES

被引：0
|
作者：
Wilke, H. [1 ]
Siena, S. [2 ]
Loos, A. [3 ]
Berghoff, K. [3 ]
Koehne, C. [4 ]
Van Cutsem, E. [5 ]
机构：
[1] Kliniken Essen Mitte, Essen, Germany
[2] Osped Niguarda CaGrande, Milan, Italy
[3] Merck KGaA, Darmstadt, Germany
[4] Klinikum Oldenburg, Oldenburg, Germany
[5] Univ Hosp Gasthuisberg, B-3000 Leuven, Belgium
来源：
ANNALS OF ONCOLOGY | 2010年 / 21卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：71 / 72
页数：2
相关论文
共 50 条
  • [1] Infusion-related reactions associated with cetuximab plus irinotecan treatment for mCRC: Data from the Mabel study
    Glynne-Jones, R.
    Siena, S.
    Thaler, J.
    Adenis, A.
    Preusser, P.
    Aranda, Aguilar E.
    Aapro, M.
    Loos, A.
    Esser, R.
    Wilke, H.
    ANNALS OF ONCOLOGY, 2007, 18 : VII75 - VII75
  • [2] Premedication and incidence of infusion-related reactions in patients with metastatic colorectal cancer treated with cetuximab plus irinotecan-based chemotherapy
    Wilke, H.
    Siena, S.
    Loos, A. H.
    Berghoff, K.
    Kohne, C.
    Van Cutsem, E.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [3] Albuterol-based premedication therapy for the prevention of cetuximab infusion-related reactions
    Tra, F.
    Fesen, M. R.
    Pianalto, M.
    Nisly, R.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [4] Montelukast-Based Premedication Regimen for Recurrent Cetuximab Infusion-Related Reactions
    Sion, Amy M.
    Milburn, Lyndsey
    Kaczmar, John M.
    JCO ONCOLOGY PRACTICE, 2021, 17 (01) : 54 - +
  • [5] Rapid infusion of infliximab biosimilars and the incidence and severity of infusion-related reactions in patients with inflammatory bowel disease
    Rusch, Caroline
    Wood, Marci
    Kennedy, Amanda G.
    Tompkins, Bradley J.
    Frasca, Joseph D.
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2022, 47 (11) : 1851 - 1857
  • [6] Reduced Incidence of Infusion-Related Reactions in Metastatic Colorectal Cancer During Treatment With Cetuximab Plus Irinotecan With Combined Corticosteroid and Antihistamine Premedication
    Siena, Salvatore
    Glynne-Jones, Robert
    Adenis, Antoine
    Thaler, Josef
    Preusser, Peter
    Aranda Aguilar, Enrique
    Aapro, Matti S.
    Loos, Anja H.
    Esser, Regina
    Wilke, Hansjochen
    CANCER, 2010, 116 (07) : 1827 - 1837
  • [7] Incidence of infusion-related reactions in patients receiving infliximab.
    Buch, MH
    Bryer, D
    Fairclough, A
    ReesEvans, B
    Emery, P
    ARTHRITIS AND RHEUMATISM, 2003, 48 (09): : S325 - S325
  • [8] Impact of pre-medication on the frequency of infusion-related reactions (IRRs) and efficacy in patients (pts) treated with cetuximab plus irinotecan for metastatic colorectal cancer (mCRC): the MABEL study
    Wilke, H.
    Siena, S.
    Thaler, J.
    Adenis, A.
    Preusser, P.
    Bridgewater, J.
    Gasparini, G.
    Esser, R.
    Loos, A.
    Glynne-Jones, R.
    EJC SUPPLEMENTS, 2007, 5 (04): : 243 - 243
  • [9] Infusion-related reactions (IRR) associated with cetuximab plus irinotecan treatment in patients with irinotecan-resistant metastatic colorectal cancer (mCRC): Findings from the MABEL study
    Siena, S.
    Glynne-Jones, R.
    Thaler, J.
    Adenis, A.
    Preusser, P.
    Aguilar, E. Aranda
    Aapro, M.
    Loos, A.
    Esser, R.
    Wilke, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [10] Incidence of infusion-related reactions in patients receiving infliximab: Recommendations for administration guidelines
    Buch, MH
    Lindsay, S
    Bryer, D
    Fairclough, A
    Rees-Evans, B
    Emery, P
    ANNALS OF THE RHEUMATIC DISEASES, 2004, 63 : 285 - 285
12345